AGP Executive Report
Last update: 5 hours agoRural Health Funding: Wyoming will receive $207 million in year two of the federal rural health fund, while Idaho’s $183 million award is slightly lower than last year’s. Idaho providers say the rushed first-round process left some applicants without clear answers; officials plan to simplify applications. AI and Drug Ads: A study of 12 AI models found chatbots were more likely to recommend an advertised medicine after seeing its ad, even when other treatments were reasonable options — raising concerns about AI health advice. Rare Disease Treatments: The FDA approved Sanofi’s Infilbray, the first drug to target neurological symptoms of type 3 Gaucher disease. Regeneron’s new myasthenia gravis treatment, Livsayis, enters a crowded market with four injections a year as a potential selling point. Alzheimer’s Care: Company-reported data found Leqembi patients in routine care had a lower rate of progression to moderate or severe dementia, but the comparison had no placebo group and cannot establish the drug’s effect.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.